Last reviewed · How we verify

Biocon Biologics UK PLC — Portfolio Competitive Intelligence Brief

Biocon Biologics UK PLC pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Herceptin Hylecta® Herceptin Hylecta® marketed HER2-targeted monoclonal antibody HER2 (human epidermal growth factor receptor 2) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Hoffmann-La Roche · 1 shared drug class
  2. Samsung Bioepis Co., Ltd. · 1 shared drug class
  3. Spanish Breast Cancer Research Group · 1 shared drug class
  4. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 shared drug class
  5. Tanvex BioPharma USA, Inc. · 1 shared drug class
  6. Zydus Lifesciences Limited · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Biocon Biologics UK PLC:

Cite this brief

Drug Landscape (2026). Biocon Biologics UK PLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biocon-biologics-uk-plc. Accessed 2026-05-16.

Related